LynxDx

About:

LynxDx offers technologies that enable early cancer detection and improvement of patient care.

Description:

LynxDx is a privately held pre-revenue diagnostic company headquartered in Ann Arbor, Michigan, with research facilities just a few miles away from the University of Michigan Health System. LynxDx currently is focused on commercializing diagnostic tools, including a diagnostic qPCR assay for COVID-19 and a urine assay to aid in the diagnosis of prostate cancer (MyProstateScore). LynxDx currently operates a CLIA-licensed high-complexity molecular diagnostics laboratory that serves to commercially provide its diagnostic assays.

Total Funding Amount:

$925000

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Ann Arbor, Michigan, United States

Founded Date:

2015-01-01

Founders:

Yashar Niknafs

Number of Employees:

51-100

Last Funding Date:

2020-01-27

IPO Status:

Private

Industries: